Clinical Trial of NXT007 for the Prophylactic Treatment of Hemophilia A in Infants and Children

Summary

The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of NXT007 prophylaxis in pediatric patients aged 0 to 11 years with severe or moderate congenital hemophilia A without factor VIII inhibitors or congenital hemophilia A of any severity (severe, moderate, and mild) with inhibitors (emicizumab-naïve and treated). Patients with hemophilia A aged ≥12 to \<18 years old with a body weight of \<40 kilograms (kg) are also able to participate.

Timeline

Start

2026-11-30

Primary completion

2028-09-30

Completion

2031-09-30

Drugs

Indications